ClinicalTrials.gg
WithdrawnNCT02201381METRICSUpdated Jul 18, 2022

Study of the Safety, Tolerability and Efficacy of Metabolic Combination Treatments on Cancer

A Phase 3 interventional study of Metabolic treatment in Cancer and Overall Survival, sponsored by Health Clinics Limited. Withdrawn at 1 site in United Kingdom. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2022-07-18.

Sponsored by Health Clinics Limited · Phase 3, Interventional, and Treatment

How we know

Why this study was withdrawn
Prospective recruitment not possible

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The purpose of this study is to determine the effectiveness of a regimen of selected metabolic treatments for patients with cancer in a real world setting and to conduct exploratory analysis on the relationship between the degree of response and changes in biochemical markers (such as glucose and lipid levels).

Read the detailed description

*This study has been designed to collect data prospectively and to retrospectively analyse data on the metabolic treatments within the cancer clinic. The retrospective study is ongoing, while the prospective study has not yet started.*

This is a real world study since this gives the best opportunity to properly examine the effect of multi-drug regimens in representative populations. Including a standard of care arm is inappropriate, in a population in which that standard of care has already been shown to be ineffective or intolerable.

Patients will be sent to the study clinic directly by their Health Care Professionals ("HCP's") .

The study will consist of a pre-screening visit to determine eligibility for inclusion into the study, an initiation visit and then a follow up visit every three months thereafter. If required, unscheduled visits may take place. Day 0 (baseline) for each patient will be the initiation visit when study treatment is started.

Prior to conducting any study-related procedures, subjects will provide written informed consent, eligibility will be assessed, a medical history and past medical records will be taken and vital signs will be measured. These records will include the stage of their disease, response to previous cancer therapy, their prior and current medications and any specific regimen they are currently on for their cancer. If prior medical records do not contain sufficient information to determine a baseline for the patient, additional blood tests and scans will be undertaken as appropriate.

Patients will be monitored quarterly thereafter when blood tests (e.g. safety parameters, glucose, cholesterol, immune response and cancer markers where applicable) and scans (where applicable) will be taken.

All patients will be on the same drug regimen (see below) at the same doses throughout the study. All patients will be followed up until they choose to leave the study, or death.

Data from all patients recruited to the study will be analysed using an Intention-to-treat (ITT) philosophy, so data will be included in the primary analysis irrespective of whether the dose regimen was followed throughout the study. If appropriate, and numbers allow, analysis will also be conducted on the Per Protocol population, comprising those patients who adhere to the regimen as prescribed.

Survival analysis methods will be used to estimate the Overall survival associated with the study regimen for each type of cancer. These estimates will be interpreted in the light of data obtained from the literature, and from eliciting expert opinion. Bayesian methods may be used where appropriate.

Tumour response, where applicable, will be summarised in tables and graphs. Estimates of response rates will be presented for each cancer type with confidence intervals.

The relationship between changes in biochemistry values (glucose, lipids) and efficacy outcomes (Progression Free Survival (PFS), Overall Survival (OS) and HRQoL) will be investigated graphically, or using other methods as appropriate.

Further exploratory analysis to investigate the effects of other factors such as age , ethnic backgrounds , cancer stage, and response to prior therapy, will also be conducted in order to try and characterise the profile of patients most likely to benefit from the study regimen.

The characteristics of patients on the regimen and those who do not stay on the regimen, for whatever reason, will be summarised to see whether there is any observed bias. If appropriate, methods will be used to adjust for any observed bias, for example using propensity scores. OS can then be assessed adjusted for this to try and mitigate for any possible risk of bias which can occur in uncontrolled studies. Furthermore, by enrolling all eligible patients over a specified time frame, it is hoped that the risk of bias should be further reduced. In addition, a large number of patients are expected to participate in the study.

02

Conditions studied

  • Cancer
  • Overall Survival

Keywords

  • Cancer
  • Cancer Treatments
  • Cancer Palliative Care
  • Metabolic
  • Metabolism
  • Existing Medicines
  • Licensed Medicines
  • Real World
  • Breast Cancer
  • Triple Negative Breast Cancer
  • Colon Cancer
  • Prostrate Cancer
  • Brain Cancer
  • Ovarian Cancer
  • Pancreatic Cancer
  • AML
  • CML
  • Leukemea
  • Metformin
  • Statins
  • Mebendazole
  • Doxycycline
  • Ibuprofen
  • Metastatic
03

In context

Neoplasms

10,837 studies on the registry are indexed under Neoplasms; 2,323 are open to participants now.

Browse Neoplasms studies →

Lead sponsor

This is the only study on the registry with Health Clinics Limited as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female 18-85 years old;
  2. Diagnosed with cancer and have had such diagnosis confirmed by scan, blood markers and/or ;
  3. Is receiving or will shortly receive standard of care therapy or has completed standard of care treatment; and
  4. Signed and dated written from the participant or LAR.

Exclusion criteria

Exclusion Criteria:

  1. Pregnant or lactating females or females who are planning a pregnancy during the course of the study;
  2. Major organ failure, renal, lung and liver failure;
  3. Participants having active liver disease or unexplained persistent elevation of serum transaminases > 3 times the ;
  4. Participants with diabetic ketoacidosis or diabetic pre-coma;
  5. Participants with a \< 60mL/min;
  6. History of cardiac or respiratory failure;
  7. History of recent myocardial infarction;
  8. Ileum, colon or stomach part or full removal rendering them unable to take the study medicines;
  9. Unable to eat or keep food or medicines down or is being fed intravenously;
  10. Is too frail and weak to withstand the study medicines in the opinion of the study doctor;
  11. Is Unlikely to survive more than 1 month under standard of care, in the opinion of the study doctor
  12. to any of the treatment drugs or ;
  13. If the patient is on any medicines with the study medicines (see Appendix 3);
  14. Mentally incapacitated and no guardian able to sign on patients Clinical study protocol, version 5.0 METRICS TRIAL, Metabolic Cancer 001 5th Apr 2016 Confidential Page 5 of 65 behalf;
  15. History or presence of alcohol or substance abuse;
  16. Participation in a clinical trial of an medicinal product that is viewed by the Study Physician to be a significant risk to the participant's safety;
  17. Direct employee of the study site.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Metabolic Treatment

    Subjects will take the following treatments and have their data collected from their medical records every 3 months. * Oral atorvastatin up to 80mg uid, for study duration. * Oral metformin up to 1000mg uid, increased to bid if tolerated after 2 weeks, for study duration. * Oral doxycycline 100mg uid, for study duration. * Oral Mebendazole 100mg uid, for study duration.

    Drug: Metabolic treatment

Interventions

  • DrugMetforminStudies of MetforminMetformin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    While subjects are being treated with the four metabolic drugs, every 3 months they will bring in their medical records and data will be collected to determine the effect of the intervention

    Also known as: Metformin, Atorvastatin, Doxycycline, Mebendazole

06

What researchers measure

Primary outcomes

  1. Overall survival

    Overall survival for all cancer types and for each cancer type (years and months)

    Time frame: up to 5 years

Secondary outcomes

  1. Change in primary tumour size cancer types and by cancer type.

    Tumour size for all cancer types and for each cancer type. Units of size vary depending on cancer type.

    Time frame: up to 5 years

  2. Change in tumour spread (metastasis)

    Tumour spread (metastasized) to other tissues/organs, for all cancer types and for each cancer type. This is measured as either 0 for no spread or 1 for confirmed spread.

    Time frame: up to 5 years

  3. Change in tumour number

    Tumour number for all cancer types and for each cancer type

    Time frame: up to 5 years

  4. Change in cancer biomarkers (blood, urine or biopsy)

    Cancer biomarkers for all cancer types and for each cancer type. Units of measurement vary depending on the cancer type. When biomarkers, either alone or in combination with other biomarkers, are raised above normal they are seen as predictive of cancer of progression. If returned to normal are indicative of treatment response.

    Time frame: up to 5 years

Other outcomes

  1. Incidence of treatment related adverse events

    Adverse events reported by the subject or their HCP. • Quarterly assessment of routine laboratory tests

    Time frame: 5 years

07

Study locations

1 site
  • Care Oncology Clinic
    London, W1G 9PP, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2022; primary completion for May 2027, 60 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 22, 2014
First posted
Jul 28, 2014
StartEst.
May 23, 2022
Primary completionEst.
May 23, 2027
CompletionEst.
Sep 23, 2027
Last update
Jul 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02201381
Lead sponsor
Health Clinics Limited
Responsible party
Sponsor
First posted
Jul 28, 2014
Start date
May 23, 2022 (estimated)
Primary completion
May 23, 2027 (estimated)
Completion
Sep 23, 2027 (estimated)
Last update
Jul 18, 2022

Study contacts

Samir Agrawal, MRCP FRCPath
principal investigator · Care Oncology Clinic

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Metformin

Start the discussion